Focused on patients. Driven by science.
AVEO is committed to bettering the lives of patients with cancer through original drug development, as well as purposeful partnerships and acquisitions.
Our pipeline
Our goal is to grow into a global oncology leader with a strong foundational portfolio that provides solutions to unmet needs in the cancer community.
AVEO aims to leverage its existing collaborations and partnerships and enter into new strategic collaborations and partnerships to continue to advance each of its product candidates.
These are investigational drugs that have not been approved by the US Food and Drug Administration (FDA).
| Candidates | Research Areas | Stage | |||
| Pre-clinical | Phase I | Phase II | Phase III | ||
| Ficlatuzumab* (Anti-HGF/c-MET IgG1 mAb) | HPV negative R/M HNSCC |  | |||
| Rilogrotug (Anti-GDF IgG1 mAb) | Cancer Cachexia | ||||
| AV-203 (Anti-ERBB3 lgG1 mAb) | Solid Tumor | ||||
| AV-353 (Anti-Notch 3 mAb) | Multiple Myeloma | ||||
*Fast track designation
For more information on LG Chem Life Sciences products in development, click here.
Investigator Sponsored Trials or Research Collaborations
These are investigational drugs and/or unapproved drug combinations that have not been approved by the US Food and Drug Administration (FDA).
| Study | Collaborating Partner/Investigator | Clinicaltrials.gov ID |
| BEAT AML Phase 1b/2 Clinical Trial Sub-study of the Beat AML® Master Clinical Trial to Evaluate the Safety and Preliminary Efficacy of Ficlatuzumab in Combination with Azacitidine and Venetoclax in Untreated Acute Myeloid Leukemia | Blood Cancer United | NCT03013998 |
| FORTUNE Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma | Eric Jonasch, MD | NCT06053658 |
| STRIKE Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma | Bradley McGregor, MD Daniel George, MD | NCT06661720 |
| IMMCO-1 Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Leighton Elliot, MD | NCT05000294 |
| Phase I/II Study Evaluating Safety and Efficacy of Tivozanib in Cholangiocarcinoma | Jonathan Hernandez, MD | NCT04645160 |
FOTIVDA in rrRCC
FOTIVDA is a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It was approved by the FDA in March 2021 for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) after 2 or more systemic therapies.
Learn moreFiclatuzumab is a potent, humanized IgG1 monoclonal antibody that targets hepatocyte growth factor, or HGF.
Learn moreRilogrotug (also known by research code AV-380) is an investigational humanized IgG1 antibody that targets growth differentiation factor 15 (GDF-15).
Learn moreAreas of interest
LG Chem Life Sciences seeks to innovate therapeutic areas where significant unmet medical needs exist. Specific therapeutic areas include:
- Metabolic diseases
- Oncology
- Immunology
Evolution of the HUMAN RESPONSE® Platform
Our portfolio originated in the HUMAN RESPONSE® Platform. This platform was designed to drive rapid development and resulted in our clinical candidates. Today, we are collaborating with the LG Chem Innovation Center to expand and advance the AVEO pipeline.